Shots: Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets […]readmore
Tags : Gilead
Shots: The P-III 1490 Study involves assessing of Biktarvy (BIC 50/FTC 200/TAF 25mg tablets) vs dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) (DTG+FTC/TAF) in ratio (1:1) patients with HIV-1 naive to […]readmore
Shots: The P-III 1489 study has assessed Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in ratio (1:1) to treat HIV-1 infection in adults for 96 weeks, testing […]readmore
Shots: Gilead will be paying Precision $445M as a milestone payment at specific development stages in addition to the double digit royalties (<19%) from sales Under the agreement, Precision will […]readmore
Shots: FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs FINCH-2 results (N= ≥153): ACR20@12wk (66 […]readmore
Shots: The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for […]readmore
Shots: NICE concludes that the ICER Yescarta vs salvage CT were above £50,000 per year making it expensive for use NICE also added considering ultra-orphan diseases that ICER for Yescarta […]readmore